Oral GLP-1 pipeline overview — all agents in development

TrialTracker_MD said:

Oral GLP-1 pipeline overview — all agents in development Pinned because it affects plans people have already made, not because it is dramatic.

That is correct as far as it goes, and here is where it stops going. The absorption variability is real, but it partly averages out over weeks — the steady-state trough is less erratic than any single day would suggest. Where it bites is in the first fortnight, when people conclude the tablet does nothing.

TrialTracker_MD said:

Oral GLP-1 pipeline overview — all agents in development Pinned because it affects plans people have already made, not because it is dramatic.

I do not accept that the fasting window is a minor inconvenience. Adherence data on daily orals with timing requirements is consistently worse than weekly injections, and a drug you take imperfectly is a lower dose than the one on the box.

Taking the question as asked, rather than the general version of it. Orforglipron is the more interesting oral story because it is not a peptide at all. Being a small molecule it does not need SNAC, does not need the fasting window, and has oral bioavailability in the tens of percent rather than about one.

FDA_TrackerJim said:

The absorption variability is real, but it partly averages out over weeks — the steady-state trough is less erratic than any single day would suggest.

Can confirm the pattern FDA_TrackerJim describes. The OASIS programme put 50mg oral in the same territory as 2.4mg injectable — around 15% mean weight loss — but it needed a dose 20 times larger to get there because almost none of the tablet is absorbed. The dose numbers are not comparable across routes and quoting them side by side confuses people.